infectious-diseases-2016_keynote

13 / 17

Volume 4, Issue 4(Suppl) J Infect Dis Ther 2016
ISSN: 2332-0877, JIDT an open access journal Infectious Diseases 2016
August 24-26, 2016
Page 71
Notes:
conferenceseries.com
August 24-26, 2016 Philadelphia, USA
&
Infectious DiseasesJoint Event on 2nd World Congress on
Pediatric Care & Pediatric Infectious Diseases
International Conference on
Eugenie Bergogne-Berezin, J Infect Dis Ther 2016, 4:4(Suppl)
Rationale approach to combat resistance
After 60 years of use of antibiotics, the world experienced antibiotic resistance. Dissemination of genes of resistance in
hospitals, in population has imposed to experts to look for measures to combat resistance, major challenges in developed
countries. Combat antibiotic resistance includes knowledge of resistance mechanisms, role of genes associated to gene cassettes,
multidrug resistance with transmissible plasmids, efflux mode of resistance, role of integrons in acquisition of resistance genes.
Among pharmacologic factors, antibiotic distribution in body at site of infection, low serum concentrations (sub-MICs) are
factors for emergence of resistance; intracellular concentrations of macrolides, fluoroquinolones are needed to eradicate intra-
cellular Legionella, chlamydia. Pharmacokinetic parameters are factors for proper use of antibiotics to combat resistance.
Research for new antibiotics is developing in Biotech companies: Rehabilitation of antibiotic classes (glycopeptides, ketolides,
oxazolidinones) to overcome resistant Gram positive bacteria; a renovated cyclic peptide colistin (polymyxin) active against
“super-bug” Acinetobacter baumannii. β-lactamase inhibitors clavulanate, sulbactam, tazobactamdid not solve resistance related
to β-lactamases C, D, carbapenemases: New β-lactamase inhibitors NXL-104, MK-7655 restore activities to imipenem, 3d
generation cephalospsorins. Newer drugs based on integrated new tools, combinatory chemistry, high speed parallel synthesis,
genomics and proteomics, able to lead to new bacterial targets: DNA replication, target genes, cellular division, secretion of
efflux pumps. Inhibition of virulence of bacterial communication systems, immunomodulatory systems are leading to new
molecules: Artilysins as cell wall targets, Torezolid, active on MRSA, Iclaprim (a diaminopyridine-dihydrofolate reductase)
inhibits VRSA. The current clinical development estimated in March 2015 the number of new antibiotics to 36 molecules in
clinical development in the US.
Biography
Eugenie Bergogne-Berezin is a Professor of Clinical Microbiology at University Diderot, Paris. She has studied MD in Medicine and PhD in Sciences in the early
1970s. She is a Chief of Department of Clinical Microbiology and research group, University Bichat Claude-Bernard and developed research on Acinetobacter
spp., (nosocomial pathogen, pathogenicity, resistance), pharmacology of antibiotics, tissue distribution (lungs, brain, bronchi), research on intestinal ecology, jejunal
flora and bacterial adhesion. She is an Adviser to pharmaceutical companies, expert in pharmacology-toxicology for the Ministry of Health, expert for international
journals. She has developed a journal Antibiotics, (Elsevier). She has published 6 medical books, many chapters in international infectious diseases books, 200
articles in scientific journals.
Eugenie Bergogne-Berezin
Centre Hospitalo-Universitaire Bichat-Claude Bernard, France